Argenx Se (ARGX) EBITDA Margin Growth (3y) (2019 - 2026)
Argenx Se (ARGX) EBITDA Margin Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9,942.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 530.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1,211.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -623.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 6,993.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -623.00 |
| Mar 31, 2026 | -1,723.00 |
| Dec 31, 2025 | 9,459.00 |
| Sep 30, 2025 | -12,815.00 |
| Jun 30, 2025 | 84,970.00 |
| Mar 31, 2025 | -103,484.00 |
| Dec 31, 2024 | 90,135.00 |
| Sep 30, 2024 | 248.00 |
| Jun 30, 2024 | 412.57 Bn |
| Mar 31, 2024 | -855.83 Bn |
| Dec 31, 2023 | 290,826.00 |
| Sep 30, 2023 | -654,834.00 |
| Jun 30, 2023 | 929,946.00 |
| Mar 31, 2023 | -47,215.00 |
| Dec 31, 2022 | 18,202.00 |
| Sep 30, 2022 | -206,034.00 |
| Jun 30, 2022 | -55,968.00 |
| Mar 31, 2022 | 106,900.00 |
| Dec 31, 2021 | -51,592.00 |
| Sep 30, 2021 | -40,071.00 |